Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05310734
Other study ID # SPN-110-21
Secondary ID
Status Recruiting
Phase Phase 4
First received
Last updated
Start date March 4, 2022
Est. completion date March 31, 2026

Study information

Verified date February 2024
Source ParaPRO LLC
Contact Kerry W Mettert, MBA, MT(ASCP
Phone 317-810-6205
Email kerrym@parapro.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

A population of approximately 50 pediatric subjects will be enrolled to assess the PK of spinosad and benzyl alcohol for 3 hours following a single, full-body topical application (open label) on a single in-clinic visit (Day 1, or Day 2 if screening only on Day 1). There will be approximately 50 subjects ages 1 month to 3 years 11 months of age enrolled with the goal of completing approximately 16 subjects. With assistance from a caregiver, Natroba will be applied over the entire body from the neck down to the toes (including the soles of the feet) and to the hairline, temples, forehead and possibly the scalp (if a scabies infestation is present on the scalp). The open-label Investigational Product (IP) will remain on the skin for at least 6 hours before removing the IP by gentle washing. The subjects will stay in the clinic until the 3-hour procedures are completed. Blood draws will be taken at 0 hours just prior to treatment, and then at 0.5 and 3.0 hours post-treatment. Heel sticks are likely to be the mode of blood collection for children less than 2 years of age. A ±5-minute time window will be allowed for all post-treatment blood samples. Removal of IP can occur by the caregiver at home after it has been on the skin for at least 6 hours before bathing the child. Safety will be assessed with adverse events (AEs), general skin and eye irritation assessments, and pre-dose and pre-discharge laboratory evaluations. Following the sample collections subjects will be released from the clinic and directed to their primary care physician for follow-up. Subjects will be provided scabies medications upon discharge to dispense to family members. These include 5% Permethrin for those in the household that are less than 4 years of age and Natroba for those in the household 4 years of age and older. Subjects who terminate early will not be given these medications to dispense to family members.


Description:

A population of approximately 50 pediatric subjects will be enrolled to assess the PK of spinosad and benzyl alcohol for 3 hours following a single, full-body topical application (open label) on a single in-clinic visit (Day 1, or Day 2 if screening only on Day 1). There will be approximately 50 subjects ages 1 month to 3 years 11 months of age enrolled with the goal of completing approximately 16 subjects. With assistance from a caregiver, Natroba will be applied over the entire body from the neck down to the toes (including the soles of the feet) and to the hairline, temples, forehead and possibly the scalp (if a scabies infestation is present on the scalp). The open-label Investigational Product (IP) will remain on the skin for at least 6 hours before removing the IP by gentle washing. The subjects will stay in the clinic until the 3-hour procedures are completed. Blood draws will be taken at 0 hours just prior to treatment, and then at 0.5 and 3.0 hours post-treatment. Heel sticks are likely to be the mode of blood collection for children less than 2 years of age. A ±5-minute time window will be allowed for all post-treatment blood samples. Removal of IP can occur by the caregiver at home after it has been on the skin for at least 6 hours before bathing the child. Safety will be assessed with adverse events (AEs), general skin and eye irritation assessments, and pre-dose and pre-discharge laboratory evaluations. Following the sample collections subjects will be released from the clinic and directed to their primary care physician for follow-up. Subjects will be provided scabies medications upon discharge to dispense to family members. These include 5% Permethrin for those in the household that are less than 4 years of age and Natroba for those in the household 4 years of age and older. Subjects who terminate early will not be given these medications to dispense to family members. Natroba (spinosad) Topical Suspension, 0.9% w/w applied by a parent/guardian in a single, full-body topical application from the neck down to the toes (including the soles of the feet) and to the hairline, temples, forehead and possibly the scalp (if a scabies infestation is present on the scalp). A blood draw will be taken from subjects just before spinosad application (t=0) and then at 0.5 and3.0 hours. The following PK parameters will be calculated for spinosad (spinosyn A and spinosyn D) and benzyl alcohol in each subject: Cmax, Tmax, and Area Under the Curve (AUC) 0-12h. Safety assessments include monitoring of AEs on study Day 1 or Day 2, general skin and eye irritation assessment on Day 1 or Day 2, laboratory assessments on Day 1 or Day 2, prior medications, and concomitant medications on Day 1 (and Day 2, if applicable). Smaller laboratory blood samples will be collected pre-dose and 12-hours post-dose prior to discharge. Pharmacokinetic (PK) parameters will be calculated by using model independent methods. Standard statistical analyses will be done on these parameters for the purpose of interpretation of the data (Cmax, Tmax and Area Under the Curve (AUC) 0-3h and will be used to assess the absorption over 3 hours post-administration in 50 subjects (1 month - 3 years 11 months). The PK parameter estimates will be computed with noncompartmental methods for each subject. Individual elapsed sampling times (actual time) will be used in the PK analysis and parameters will be computed for each subject. Descriptive summaries of the plasma concentration levels for both spinosad (spinosyn A and spinosyn D) and benzyl alcohol observed at each nominal time point will be provided. Descriptive summaries of the PK parameter estimates will also be completed. Summary statistics for continuous variables will include number of non-missing observations, mean, standard deviation, coefficient of variation (CV%), median, minimum, and maximum, geometric mean and standard error of the geometric mean. The safety endpoints include the evaluation of adverse events, general skin and eye irritation assessments, clinical laboratory assessments, and use of prior medications and concomitant medications. Additionally, the descriptive changes from baseline (pre-dose) to final assessment (pre-discharge) will be calculated for applicable parameters.


Recruitment information / eligibility

Status Recruiting
Enrollment 50
Est. completion date March 31, 2026
Est. primary completion date November 30, 2025
Accepts healthy volunteers No
Gender All
Age group 1 Month to 4 Years
Eligibility Inclusion Criteria: 1. Male or female, ages 1 month to 3 years and 11 months. 2. Must have active scabies infestation confirmed by clinical signs and symptoms (evidence of burrows or presence of scabies inflammatory/non-inflammatory lesions and pruritus) as well as by burrow ink test (BIT) to demonstrate the presence of burrowing mites. 3. Generally, in good health based on medical history and clinical assessments. 4. Normal-appearing skin in non-infested areas. 5. No history of chronic or recurrent dermatologic disease. 6. Willingness to comply with the study procedures including blood collections and application of study treatment in-clinic. Exclusion Criteria: 1. Presence of crusted scabies (Norwegian scabies). 2. Allergies or intolerance to ingredients in the Investigational Product. 3. Known renal or hepatic impairment. 4. Treatment with scabicide within the prior 2 weeks. 5. Immunodeficiency (including HIV infection) as reported in Medical History. 6. Signs or symptoms of systemic infection. 7. Administration of systemic therapy for infectious disease within the prior 2 weeks. 8. Receipt of any investigational product within the prior 4 weeks. 9. Medications used for itching or other indication that contain benzyl alcohol or other alcohols within the past 7 days. 10. Over-the-counter cortisone products within the past 7 days. 11. Oral prescription medications and/or antibiotics within the past 7 days. 12. Any other conditions that, at the investigator's discretion, may interfere with the study conduct, or which might confound the interpretation of the study results, or which may put the subject at undue risk.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Spinosad Topical
A topical suspension indicated for the treatment of scabies is used for this PK and Safety Study

Locations

Country Name City State
United States Elixir Research Group Houston Texas
United States Velocity Clinical Research Lafayette Louisiana
United States L&C Professional Medical Research Institute Miami Florida

Sponsors (6)

Lead Sponsor Collaborator
ParaPRO LLC BioAgilytix, Concentrics Research, Inotiv Laboratories, Iqvia Pty Ltd, Medpace, Inc.

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Cmax for Spinosyn A Peak Plasma Concentration of Spinosyn A in Natroba (spinosad) Topical Suspension, 0.9% Blood samples collected up to 3 hours post treatment - 0 (pre-treatment), 0.5 and 3.0 hours post-treatment.
Primary Tmax for Spinosyn A The time after administration of Natroba (spinosad) Topical Suspension, 0.9% when the maximum plasma concentration is reached for Spinosyn A. Blood samples collected up to 3 hours post treatment - 0 (pre-treatment), 0.5 and 3.0 hours post-treatment.
Primary Area Under the Curve (AUC) 0-3 for Spinosyn A Area under the plasma concentration versus time curve Area Under the Curve (AUC) of Spinosyn A in Natroba (spinosad) Topical Suspension, 0.9%. Blood samples collected up to 3 hours post treatment - 0 (pre-treatment), 0.5 and 3.0 hours post-treatment.
Primary Cmax for Spinosyn D Peak Plasma Concentration of Spinosyn D in Natroba (spinosad) Topical Suspension, 0.9% Blood samples collected up to 3 hours post treatment - 0 (pre-treatment), 0.5 and 3.0 hours post-treatment.
Primary Tmax for Spinosyn D The time after administration of Natroba (spinosad) Topical Suspension, 0.9% when the maximum plasma concentration is reached for Spinosyn D. Blood samples collected up to 3 hours post treatment - 0 (pre-treatment), 0.5 and 3.0 hours post-treatment.
Primary Area Under the Curve (AUC) 0-3 for Spinosyn D Area under the plasma concentration versus time curve Area Under the Curve (AUC) of Spinosyn D in Natroba (spinosad) Topical Suspension, 0.9%. Blood samples collected up to 3 hours post treatment - 0 (pre-treatment), 0.5 and 3.0 hours post-treatment.
Primary Cmax for Benzyl Alcohol Peak Plasma Concentration of benzyl alcohol (above Limit of Quantitation (1.0 µg/mL) in Natroba (spinosad) Topical Suspension, 0.9%. Blood samples collected up to 3 hours post treatment - 0 (pre-treatment), 0.5 and 3.0 hours post-treatment.
Primary Tmax for Benzyl Alcohol The time after administration of Natroba (spinosad) Topical Suspension, 0.9% when the maximum plasma concentration is reached for benzyl alcohol. Blood samples collected up to 3 hours post treatment - 0 (pre-treatment), 0.5 and 3.0 hours post-treatment.
Primary Area Under the Curve (AUC) 0-3 for Benzyl Alcohol Area under the plasma concentration versus time curve Area Under the Curve (AUC) of benzyl alcohol in Natroba (spinosad) Topical Suspension, 0.9%. Blood samples collected up to 3 hours post treatment - 0 (pre-treatment), 0.5 and 3.0 hours post-treatment.
Primary Treatment Emergent Adverse Events Treatment emergent AEs will be coded using MedDRA and summarized by System Organ Class and Preferred Term. Through study completion, 3 hours
Primary Change in General Skin Irritation The skin assessment will include documentation of presence or absence of irritation. Through study completion, 3 hours
Primary Change in General Eye Irritation The eye assessment will include documentation of presence or absence of irritation with a rating scale 0-3. 0 - no irritation, 1 - mild scleral, lid and/or lid injection with conjuctival erythema; 2 - moderate scleral and/or lid injection with conjunctival erythema; 3 - severe scleral and/or lid injection with conjunctival erythema and purulent drainage. Through study completion, 3 hours
See also
  Status Clinical Trial Phase
Completed NCT02572986 - A Study to Evaluate the Therapeutic Equivalence of Generic Permethrin Cream 5% to Elimite® in the Treatment of Scabies Phase 3
Completed NCT00884728 - Evaluation of a Regional Healthy Skin Program in Remote Aboriginal Communities of Australia's Northern Territory N/A
Completed NCT05025696 - Efficacy and Side Effects of Blacksoap® as Adjuvant Therapy of Scabies N/A
Completed NCT04205669 - Comparing the Effectiveness of Individual vs. Household Treatment for Scabies in Lambaréné, Gabon Phase 4
Completed NCT02254564 - PCR (Polymerase Chain Reaction) Assay for Diagnosis of Sarcoptes Scabiei
Not yet recruiting NCT06404333 - Evaluating Pediatric Ivermectin in Children Under 15 kg (EPIC-15) Phase 2
Completed NCT03676140 - Safety of Co-administration of IDA and Azithromycin for NTDs ( ComboNTDs ) Phase 3
Recruiting NCT05875441 - Efficacy and Safety Study of Moxidectin in Adults With Scabies Phase 2
Completed NCT02978508 - Bio-equivalence Study Comparing Permethrin Cream, 5% With Elimite in Patients With Active Scabies. Phase 3
Recruiting NCT04332068 - Ivermectin Safety in Small Children Phase 2
Recruiting NCT04844905 - Adjunctive Ivermectin Mass Drug Administration for Malaria Control Phase 3
Not yet recruiting NCT06380452 - Therapy for Scabies With Two Differently Concentrated Permethrin Creams Phase 3
Completed NCT00604084 - Veron Scabies Education and Eradication Program N/A
Completed NCT02485717 - Phase 3 Trial to Assess the Safety and Efficacy of Natroba for the Treatment of Scabies Phase 3
Completed NCT02485704 - Phase 3 Trial to Assess the Safety and Efficacy of Natroba for the Treatment of Scabies Phase 3
Recruiting NCT04931680 - Risk Factors for Treatment Failure of Scabies in Autochthonous Populations of French Guiana (GUYAGALE)
Completed NCT06396507 - Sulfur vs. Different Regimes of Permethrin for Scabies Phase 3
Completed NCT05862701 - Comparison of Topical 5% Permethrin and Topical 10% Sulfur in the Treatment of Scabies Phase 1
Not yet recruiting NCT05500326 - Ivermectin Therapy for Scabies Infection in Children Younger Than 5 Years of Age (ITCHY Study) Phase 2
Recruiting NCT04814511 - Escalated Therapy of Scabies With INFECTOSCAB 5% (Permethrin) Phase 3